The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 01, 2020

Filed:

Apr. 17, 2020
Applicant:

Precision Biosciences, Inc., Durham, NC (US);

Inventors:

Derek Jantz, Durham, NC (US);

James Jefferson Smith, Morrisville, NC (US);

Assignee:

Precision BioSciences, Inc., Durham, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); C12N 15/52 (2006.01); C12N 9/22 (2006.01); A61P 31/20 (2006.01); A61K 9/51 (2006.01); A61K 38/43 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/22 (2013.01); A61K 9/51 (2013.01); A61K 38/43 (2013.01); A61P 31/20 (2018.01); C12N 15/52 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); C12N 2730/10122 (2013.01); C12N 2750/14141 (2013.01);
Abstract

The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV). The present invention also encompasses methods of using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of a HBV infection, or treating hepatocellular carcinoma (HCC). Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or HCC.


Find Patent Forward Citations

Loading…